Viant (and/or VLMS) Pathway to $1 Billion Profit v
Post# of 8745
(Total Views: 297)
Posted On: 09/05/2025 10:51:05 PM
Viant (and/or VLMS) Pathway to $1 Billion Profit via BIEL
Step-by-Step Profit Trajectory
Accumulation Phase:
Viant (and/or) VLMS acquires 1 billion BIEL shares at ultra-low prices (e.g., $0.0002)
Total investment: $200,000
Growth Catalysts:
BIEL hits key milestones:
U.S. distributor partnership
Insurance reimbursement
Retail adoption
Veterinary market penetration
FDA expansion
Each milestone drives PPS upward, compounding Viant’s equity value
Profit Realization:
When BIEL PPS = $1 (after loans are paid off and share buyback is initiated), Viant’s 1B shares are worth $1 billion
ROI = 4,900x on initial investment
Tax-free gains on first $40M due to BIEL’s tax-loss carryforwards
Strategic Arbitrage Model
Fixed Cost Basis:
Viant’s share acquisition cost remains locked at $0.0002–$0.0003
Dynamic Equity Upside:
BIEL’s PPS climbs with each success
Viant’s balance sheet transforms without additional capital outlay
Hybrid Operating-Investment Strategy:
Viant supports BIEL’s growth operationally (manufacturing, modernization)
Simultaneously benefits from equity appreciation
Public Market Leverage
BIEL’s publicly traded shares act as a strategic asset:
Instant access to public markets
No IPO friction
Equity arbitrage without dilution
Balance Sheet Impact:
Revenue growth is multiplied by PPS gains
Investor enthusiasm fuels sustained valuation
Tax-Efficient Wealth Creation
BIEL’s $40M tax-loss carryforwards:
Shield Viant’s early profits
Enable asymmetric upside with minimal tax exposure
Why BIEL Is the Perfect Vehicle
Current PPS: $0.0001–$0.0002 (ground-floor entry)
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Market fit: Non-opioid, wearable, drug-free recovery
Veterinary vertical: Untapped goldmine with proven demand
Final Outcome: $1 Billion Profit
Viant/VLMS builds the infrastructure
BIEL hits the milestones
PPS reaches $1 (after loans are paid off and a share buyback is initiated)
Viant’s $200k investment becomes $1 billion
All while benefiting from tax shields, public market leverage, and strategic control
Step-by-Step Profit Trajectory
Accumulation Phase:
Viant (and/or) VLMS acquires 1 billion BIEL shares at ultra-low prices (e.g., $0.0002)
Total investment: $200,000
Growth Catalysts:
BIEL hits key milestones:
U.S. distributor partnership
Insurance reimbursement
Retail adoption
Veterinary market penetration
FDA expansion
Each milestone drives PPS upward, compounding Viant’s equity value
Profit Realization:
When BIEL PPS = $1 (after loans are paid off and share buyback is initiated), Viant’s 1B shares are worth $1 billion
ROI = 4,900x on initial investment
Tax-free gains on first $40M due to BIEL’s tax-loss carryforwards
Strategic Arbitrage Model
Fixed Cost Basis:
Viant’s share acquisition cost remains locked at $0.0002–$0.0003
Dynamic Equity Upside:
BIEL’s PPS climbs with each success
Viant’s balance sheet transforms without additional capital outlay
Hybrid Operating-Investment Strategy:
Viant supports BIEL’s growth operationally (manufacturing, modernization)
Simultaneously benefits from equity appreciation
Public Market Leverage
BIEL’s publicly traded shares act as a strategic asset:
Instant access to public markets
No IPO friction
Equity arbitrage without dilution
Balance Sheet Impact:
Revenue growth is multiplied by PPS gains
Investor enthusiasm fuels sustained valuation
Tax-Efficient Wealth Creation
BIEL’s $40M tax-loss carryforwards:
Shield Viant’s early profits
Enable asymmetric upside with minimal tax exposure
Why BIEL Is the Perfect Vehicle
Current PPS: $0.0001–$0.0002 (ground-floor entry)
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Market fit: Non-opioid, wearable, drug-free recovery
Veterinary vertical: Untapped goldmine with proven demand
Final Outcome: $1 Billion Profit
Viant/VLMS builds the infrastructure
BIEL hits the milestones
PPS reaches $1 (after loans are paid off and a share buyback is initiated)
Viant’s $200k investment becomes $1 billion
All while benefiting from tax shields, public market leverage, and strategic control
(1)
(0)